AR069568A1 - Vacuna de la malaria que emplea vectores adenovirales recombinantes - Google Patents
Vacuna de la malaria que emplea vectores adenovirales recombinantesInfo
- Publication number
- AR069568A1 AR069568A1 ARP080105281A ARP080105281A AR069568A1 AR 069568 A1 AR069568 A1 AR 069568A1 AR P080105281 A ARP080105281 A AR P080105281A AR P080105281 A ARP080105281 A AR P080105281A AR 069568 A1 AR069568 A1 AR 069568A1
- Authority
- AR
- Argentina
- Prior art keywords
- viral vector
- adenoviral vectors
- recombinant adenoviral
- malaria vaccine
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Un vector adenovírico de simio deficiente de replicacion C7 que codifica una proteína que comprende la proteína CS de P. falciparum o un fragmento de la misma por ejemplo como se muestra en la SEC ID N°: 1 o la SEC ID N°: 3. También procedimientos de preparacion de dicho vector vírico y al uso del vector vírico en el tratamiento/prevencion de infeccion por malaria. Se describen también composiciones, vacunas y kits que comprenden dicho vector vírico. En un aspecto, se emplea un vector vírico C7 sintético. El vector vírico C7 puede coadministrarse o coformularse con un antígeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99280207P | 2007-12-06 | 2007-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069568A1 true AR069568A1 (es) | 2010-02-03 |
Family
ID=40591828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105281A AR069568A1 (es) | 2007-12-06 | 2008-12-04 | Vacuna de la malaria que emplea vectores adenovirales recombinantes |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2227550A2 (es) |
| JP (1) | JP2011505796A (es) |
| KR (1) | KR20100108544A (es) |
| CN (1) | CN101939438A (es) |
| AR (1) | AR069568A1 (es) |
| AU (1) | AU2008333208A1 (es) |
| BR (1) | BRPI0819889A2 (es) |
| CA (1) | CA2707245A1 (es) |
| CL (1) | CL2008003614A1 (es) |
| CO (1) | CO6300795A2 (es) |
| CR (1) | CR11537A (es) |
| DO (1) | DOP2010000164A (es) |
| IL (1) | IL205953A0 (es) |
| MA (1) | MA32003B1 (es) |
| MX (1) | MX2010006207A (es) |
| PE (1) | PE20091106A1 (es) |
| TW (1) | TW200938633A (es) |
| UY (1) | UY31510A1 (es) |
| WO (1) | WO2009071613A2 (es) |
| ZA (1) | ZA201003851B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| NZ616304A (en) * | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| EP1569515A4 (en) * | 2002-10-23 | 2006-04-26 | Glaxosmithkline Biolog Sa | MALARIA vaccine method |
| WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| WO2005063805A1 (en) * | 2003-12-23 | 2005-07-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection |
| LT2163260T (lt) * | 2004-01-23 | 2017-06-26 | Msd Italia S.R.L. | Šimpanzės adenoviruso vakcinos nešikliai |
| KR20070104881A (ko) * | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| SG173377A1 (en) * | 2006-07-18 | 2011-08-29 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
| MX362698B (es) * | 2007-03-02 | 2019-02-01 | Glaxosmithkline Biologicals Sa | Metodo novedoso y composiciones. |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
-
2008
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Application Discontinuation
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en active Application Filing
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
-
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200938633A (en) | 2009-09-16 |
| MA32003B1 (fr) | 2011-01-03 |
| AU2008333208A1 (en) | 2009-06-11 |
| EP2227550A2 (en) | 2010-09-15 |
| ZA201003851B (en) | 2012-11-28 |
| PE20091106A1 (es) | 2009-08-24 |
| MX2010006207A (es) | 2010-10-04 |
| UY31510A1 (es) | 2009-08-03 |
| CL2008003614A1 (es) | 2010-01-15 |
| KR20100108544A (ko) | 2010-10-07 |
| DOP2010000164A (es) | 2010-07-31 |
| WO2009071613A2 (en) | 2009-06-11 |
| CO6300795A2 (es) | 2011-07-21 |
| CA2707245A1 (en) | 2009-06-11 |
| WO2009071613A3 (en) | 2009-08-13 |
| IL205953A0 (en) | 2010-11-30 |
| JP2011505796A (ja) | 2011-03-03 |
| BRPI0819889A2 (pt) | 2015-06-16 |
| CR11537A (es) | 2010-08-18 |
| CN101939438A (zh) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
| MX347997B (es) | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. | |
| EA201170812A1 (ru) | Способы и композиции для применения вакцины против кокцидиоза | |
| EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| JP2016146837A5 (es) | ||
| PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| WO2006115843A3 (en) | Nipah virus vaccines | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| MXPA06013388A (es) | Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. | |
| AR093712A1 (es) | Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento | |
| JP2014521605A5 (es) | ||
| AR069568A1 (es) | Vacuna de la malaria que emplea vectores adenovirales recombinantes | |
| IN2012DN02692A (es) | ||
| ZA202107428B (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
| TW200637573A (en) | Peptide for delivery of mucosal vaccines | |
| CO2017005830A2 (es) | Composiciones de vacuna para el virus del dengue | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| BR112014001287A2 (pt) | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina | |
| WO2007101948A3 (fr) | Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus | |
| WO2007127372A3 (en) | Genetic adjuvants for viral vaccines | |
| HK1094871A1 (en) | Recombinant vaccine against japanese encephalitis virus [jev] infection and a method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |